Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 9:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 208 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Simvastatin (Zocor) Clear all
Completed Phase 4 Interventional

A Study to Determine the Effect of WelChol Tablets on Cholesterol in Patients Who Have Been Taking Simvastatin for at Least 4 Weeks.

NCT00753779
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
colesevelam HCl tablets, and simvastatin tablets, simvastatin tablets and colesevelam HCl placebo
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
14
States / cities
Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 4, 2026, 9:36 AM EDT
Terminated Not applicable Interventional Results available

Women With Chest Pain and Normal Coronary Arteries Study

NCT00743197
View directory record Official record
Conditions
Chest Pain
Interventions
Aspirin, Lisinopril, Simvastatin, Lovaza, Therapeutic Lifestyle Changes
Drug · Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 90 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 1 Interventional

Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)

NCT00655993
View directory record Official record
Conditions
COPD, Inflammation
Interventions
simvastatin
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
40 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 4, 2026, 9:36 AM EDT
Recruiting Not applicable Interventional

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

NCT07704918
View directory record Official record
Conditions
Melanoma
Interventions
Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin

NCT02542969
View directory record Official record
Conditions
Healthy
Interventions
Simvastatin, Rosuvastatin, MGL-3196
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 2, 2022 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

NCT02714569
View directory record Official record
Conditions
Dyslipidemias
Interventions
LY3202328, Placebo, Atorvastatin, Simvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 4, 2026, 9:36 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

DNA Diagnostic System for Statin Safety and Efficacy

NCT00767130
View directory record Official record
Conditions
Hypercholesterolemia, Myopathy
Interventions
Not listed
Lead sponsor
Genomas, Inc
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
3
States / cities
San Francisco, California • Hartford, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2008 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants

NCT01689623
View directory record Official record
Conditions
Healthy Participants
Interventions
TMC435, Atorvastatin, Simvastatin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
19 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 4, 2013 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]

NCT03011931
View directory record Official record
Conditions
Celiac Disease
Interventions
Simvastatin
Drug
Lead sponsor
Entero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms

NCT01032993
View directory record Official record
Conditions
Pain, Weakness, Cramps, Myalgia or Myositis Nos, HMG COA Reductase Inhibitor Adverse Reaction
Interventions
Coenzyme Q10, Placebo
Dietary Supplement · Other
Lead sponsor
Catherine Buettner
Other
Eligibility
21 Years and older
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug Interaction Study Between Simvastatin and GSK376501

NCT00605449
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
GSK376501
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 4, 2026, 9:36 AM EDT
Active, not recruiting Phase 2 Interventional

Effects of Simvastatin on Uterine Leiomyoma Size

NCT03400826
View directory record Official record
Conditions
Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
Interventions
Simvastatin 40mg, Placebo 40 mg
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 4, 2026, 9:36 AM EDT
Not yet recruiting Early Phase 1 Interventional

Topical Simvastatin for Treating Infantile Hemangioma

NCT06273111
View directory record Official record
Conditions
Hemangioma Skin
Interventions
5% simvastatin ointment
Drug
Lead sponsor
Joyce Teng
Other
Eligibility
3 Months to 6 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study on Possible Interactions Between Protease Inhibitors (Anti-HIV Drugs) and Drugs Which Lower the Level of Fat in Your Blood

NCT00000941
View directory record Official record
Conditions
HIV Infections
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2002
U.S. locations
13
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 4, 2026, 9:36 AM EDT
Active, not recruiting Not applicable Interventional

A Study for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

NCT03127631
View directory record Official record
Conditions
Prostate Cancer, Cardiovascular Disease
Interventions
Nutrition, Exercise, Smoking cessation, Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin), ACE inhibitor
Behavioral · Drug
Lead sponsor
McMaster University
Other
Eligibility
45 Years and older · Male only
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
4
States / cities
Augusta, Georgia • Kansas City, Kansas • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients

NCT03452891
View directory record Official record
Conditions
Periodontal Diseases
Interventions
Methylcellulose, Simvastatin-Methylcellulose
Other · Drug
Lead sponsor
University of Nebraska
Other
Eligibility
40 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Not applicable Interventional Results available

Statin Therapy Versus Placebo Prior to Prostatectomy

NCT00572468
View directory record Official record
Conditions
Cancer, Prostate Cancer
Interventions
Simvastatin, Placebo
Drug · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Durham, North Carolina • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)

NCT01507831
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Placebo (for alirocumab), Alirocumab, Lipid-Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
115
States / cities
Huntsville, Alabama • Gilbert, Arizona • Sierra Vista, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Statin Use on Aldosterone Secretion

NCT02871687
View directory record Official record
Conditions
Healthy Subjects
Interventions
Simvastatin, Pravastatin, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 4, 2026, 9:36 AM EDT
Terminated Not applicable Interventional Results available

Feasibility Study of Simvastatin in Hodgkin's Lymphoma Survivors

NCT00746603
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
Simvastatin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 35 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

NCT00812955
View directory record Official record
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions
ABT-143, simvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
129
States / cities
Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

NCT01623115
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
26
States / cities
Bell Gardens, California • Long Beach, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 4, 2026, 9:36 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Efavirenz and Nelfinavir on the Blood Levels of Certain Lipid-Lowering Drugs

NCT00017758
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Lipodystrophy
Interventions
Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
10
States / cities
Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2006 · Synced Oct 4, 2026, 9:36 AM EDT